If you have non-small-cell lung cancer (NSCLC) with an EGFR mutation, your health care provider may recommend a new medicine called Datroway (datopotamab deruxtecan-dlnk). NSCLC is the most common ...
Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy. The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab ...
DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...
Patients with triple-negative breast cancer who were given the drug, Datroway, had a median overall survival of 23.7 months, compared with 18.7 months for those given just chemotherapy. Patients on ...
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this patient population DATROWAY also demonstrated a highly ...
Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results